Back

Impact of mitral valvular and subvalvular abnormalities on response to mavacamten in obstructive hypertrophic cardiomyopathy

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Echocardiography in cardiomyopathy: from research to real-world practice Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Morgane Herry

Hospital Lariboisiere, Paris (France)

4 More presentations in this session

Presentation thumbnail
Diastolic improvement and left atrial reverse remodelling with mavacamten in obstructive hypertrophic cardiomyopathy: real-world echocardiographic data from China
Miss W. Liang (Shanghai, CN)
Abstract
Presentation thumbnail
Echocardiographic assessment of right ventricular hypertrophy and right ventricular-pulmonary artery coupling in hypertrophic cardiomyopathy—implications for outcomes
Mrs A. Clement (Iasi, RO)
Abstract
Presentation thumbnail
Incremental prognostic value of advanced echocardiographic over standard 2D assessment in a real-world clinical population
Doctor G. Benzoni (Milan, IT)
Abstract
Presentation thumbnail
Cardiac function evaluated with myocardial strain of the four cardiac chambers in adult patients with genetic familial hypercholesterolemia
Doctor L. Soulat-Dufour (Paris, FR)
Abstract

Access the full session

Session thumbnail
Echocardiography in cardiomyopathy: from research to real-world practice

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Mitral regurgitation in obstructive hypertrophic cardiomyopathy: assessing the impact of mavacamten
13 December 2024
thumbnail
Congress Presentation
Hemodynamic and symptomatic response in real-world patients with hypertrophic obstructive cardiomyopathy and myosin inhibitor therapy
1 September 2025
thumbnail
Congress Presentation
A rare case of abnormal formation of mitral valve : tumor or not?
3 March 2019
thumbnail
Congress Presentation
Clinical effects of metoprolol in obstructive hypertrophic cardiomyopathy (TEMPO). A randomized, double-blinded, placebo-controlled crossover trial
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources